Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BeiGene In-licenses Janssen Onco-Compounds | Contract Pharma

What are you searching for?

Sign in
Breaking News

BeiGene In-licenses Janssen Onco-Compounds

Starts co-development program for intetumumab

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BeiGene, Ltd. has entered into exclusive in-licensing and co-development agreements with Janssen Pharmaceutica NV for two clinical-stage oncology compounds. BeiGene will in-license intetumumab (CNTO-95) for clinical development and commercialization in Australia, China, Hong Kong, New Zealand, Korea, Singapore and Taiwan. The two companies will co-develop intetumumab in multiple cancer indications. BeiGene will receive a royalty on global sales outside of these regions. Both parties will share intetumumab development costs. Additionally, BeiGene will in-license MTKi-327 and retain global rights for development and commercialization for an undisclosed upfront payment to Janssen. Janssen is eligible for milestone and royalty payments for MTKi-327.
 
“We are extremely excited to progress these two promising compounds in clinical trials and delighted to be able to initiate a co-development program with intetumumab,” said Peter Ho, M.D., Ph.D., president and co-founder, BeiGene. “Both intetumumab with its encouraging data from Phase II clinical trials and MTKi-327, an inhibitor of several critical cancer signaling pathways, represent promising molecules that have great potential to address the unmet medical needs of oncology patients in China and the Asia-Pacific region.”
 
“We look forward to working with Janssen as a strategic collaborator as we strive to build world-class oncology capabilities in China,” said John Oyler, chief executive officer and co-founder, BeiGene.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics